PURPOSE: Modern imaging technologies such as CT, PET, SPECT, and MRI employ contrast agents to visualize the tumor microenvironment, providing information on malignancy and response to treatment. Currently, all clinical imaging agents require chemical labeling, i.e. with iodine (CT), radioisotopes (PET/SPECT), or paramagnetic metals (MRI). The goal was to explore the possibility of using simple D-glucose as an infusable biodegradable MRI agent for cancer detection. METHODS: D-glucose signals were detected using chemical exchange saturation transfer (glucoCEST) MRI of its hydroxyl groups. Feasibility was established in phantoms as well as in vivo using two human breast cancer cell lines, MDA-MB-231 and MCF-7, implanted orthotopically in nude mice. PET and contrast-enhanced MRI were also acquired. RESULTS: Both tumor types exhibited significant glucoCEST signal enhancement during systemic sugar infusion (mild hyperglycemia), allowing their noninvasive visualization. GlucoCEST showed differences between types, while PET and CE-MRI did not. Data are discussed in terms of signal contributions from the increased vascular volume in tumors and especially from the acidic extracellular extravascular space (EES), where glucoCEST signal is expected to be enhanced due to a slow down of hydroxyl proton exchange. CONCLUSIONS: This observation opens up the possibility for using simple non-toxic sugars as contrast agents for cancer detection with MRI by employing hydroxyl protons as a natural label.
PURPOSE: Modern imaging technologies such as CT, PET, SPECT, and MRI employ contrast agents to visualize the tumor microenvironment, providing information on malignancy and response to treatment. Currently, all clinical imaging agents require chemical labeling, i.e. with iodine (CT), radioisotopes (PET/SPECT), or paramagnetic metals (MRI). The goal was to explore the possibility of using simple D-glucose as an infusable biodegradable MRI agent for cancer detection. METHODS:D-glucose signals were detected using chemical exchange saturation transfer (glucoCEST) MRI of its hydroxyl groups. Feasibility was established in phantoms as well as in vivo using two humanbreast cancer cell lines, MDA-MB-231 and MCF-7, implanted orthotopically in nude mice. PET and contrast-enhanced MRI were also acquired. RESULTS: Both tumor types exhibited significant glucoCEST signal enhancement during systemic sugar infusion (mild hyperglycemia), allowing their noninvasive visualization. GlucoCEST showed differences between types, while PET and CE-MRI did not. Data are discussed in terms of signal contributions from the increased vascular volume in tumors and especially from the acidic extracellular extravascular space (EES), where glucoCEST signal is expected to be enhanced due to a slow down of hydroxyl proton exchange. CONCLUSIONS: This observation opens up the possibility for using simple non-toxic sugars as contrast agents for cancer detection with MRI by employing hydroxyl protons as a natural label.
Authors: Craig K Jones; Daniel Polders; Jun Hua; He Zhu; Hans J Hoogduin; Jinyuan Zhou; Peter Luijten; Peter C M van Zijl Journal: Magn Reson Med Date: 2011-11-14 Impact factor: 4.668
Authors: Kejia Cai; Mohammad Haris; Anup Singh; Feliks Kogan; Joel H Greenberg; Hari Hariharan; John A Detre; Ravinder Reddy Journal: Nat Med Date: 2012-01-22 Impact factor: 53.440
Authors: Meiyun Wang; Xiaohua Hong; Che-Feng Chang; Qiang Li; Bo Ma; Hong Zhang; Sinan Xiang; Hye-Young Heo; Yi Zhang; Dong-Hoon Lee; Shanshan Jiang; Richard Leigh; Raymond C Koehler; Peter C M van Zijl; Jian Wang; Jinyuan Zhou Journal: Magn Reson Med Date: 2015-04-16 Impact factor: 4.668
Authors: Xiaolei Song; Xing Yang; Sangeeta Ray Banerjee; Martin G Pomper; Michael T McMahon Journal: Contrast Media Mol Imaging Date: 2014-04-28 Impact factor: 3.161
Authors: Ouri Cohen; Shuning Huang; Michael T McMahon; Matthew S Rosen; Christian T Farrar Journal: Magn Reson Med Date: 2018-05-13 Impact factor: 4.668